Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Assets (2016 - 2025)

Vistagen Therapeutics' Non-Current Assets history spans 12 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 23.46% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $8.3 million, down 21.93%, while the annual FY2025 figure was $2.3 million, 24.02% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.8 million at Vistagen Therapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.2 million in Q1 2021 and bottomed at $1.8 million in Q4 2025.
  • The 4-year median for Non-Current Assets is $3.0 million (2023), against an average of $3.0 million.
  • The largest annual shift saw Non-Current Assets grew 2.34% in 2021 before it fell 24.02% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $3.8 million in 2021, then dropped by 21.56% to $3.0 million in 2023, then dropped by 19.91% to $2.4 million in 2024, then dropped by 23.46% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Non-Current Assets are $1.8 million (Q4 2025), $2.0 million (Q3 2025), and $2.2 million (Q2 2025).